SG Americas Securities LLC Makes New Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

SG Americas Securities LLC purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 68,346 shares of the biotechnology company's stock, valued at approximately $871,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 25.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock valued at $208,889,000 after buying an additional 2,222,223 shares during the last quarter. Slate Path Capital LP grew its position in shares of Arrowhead Pharmaceuticals by 7.1% in the 4th quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company's stock valued at $98,362,000 after acquiring an additional 347,000 shares during the period. Norges Bank bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $38,622,000. Northern Trust Corp grew its position in shares of Arrowhead Pharmaceuticals by 11.4% in the 4th quarter. Northern Trust Corp now owns 1,484,419 shares of the biotechnology company's stock valued at $27,907,000 after acquiring an additional 151,654 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Arrowhead Pharmaceuticals by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,017,720 shares of the biotechnology company's stock valued at $19,133,000 after acquiring an additional 10,785 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of the firm's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $11.49, for a total transaction of $583,692.00. Following the transaction, the chief executive officer now directly owns 3,921,255 shares of the company's stock, valued at approximately $45,055,219.95. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ARWR. Chardan Capital reissued a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. Finally, Citigroup decreased their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $43.71.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR traded down $0.30 during mid-day trading on Friday, reaching $15.32. 2,775,005 shares of the company were exchanged, compared to its average volume of 1,544,314. The company's 50-day simple moving average is $14.61 and its 200-day simple moving average is $16.96. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $2.12 billion, a P/E ratio of -10.94, a P/E/G ratio of 18.37 and a beta of 0.96. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81. The company had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same quarter in the prior year, the business posted ($1.02) EPS. As a group, research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.